glucagon

all catalysts(0)

nothing on the calendar yet

News(10)

• Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
  Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among oth…
  biospace · 14d ago
• Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
  Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a wee…
  endpoints · 14d ago
• Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
  An experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope that the ubiquitous weight loss meds can be effectively harnessed again…
  fiercebiotech · 14d ago
• Lilly, with new data, to seek FDA approval of obesity drug retatrutide
  The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
  biopharma_dive · 19d ago
• Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
  With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expe…
  biospace · 19d ago
• Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
  Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug…
  fiercebiotech · 19d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
  The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…
  endpoints · 2mo ago
• STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
  Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
  stat · 2mo ago
• Boehringer dual-acting obesity shot hits mark in Phase 3 trial
  Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
  biopharma_dive · 3mo ago